Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- National, Rosai Hospitals to Buy 9,000 Products in First Joint Purchasing, HQ to Buy Generics by Bulk
April 16, 2012
- Elmed Eisai Found to Make Good Impression on Pharmacists: Survey
April 16, 2012
- Over 60% of Drug Makers Increased Hiring of New Graduates in 2012: Jiho Survey
April 16, 2012
- Ain Pharmaciez to Introduce Electronic Drug Notebooks at All Its Group Stores in July
April 16, 2012
- Takeda to Acquire URL Pharma, Boost US Business Base Through Field of Gout
April 13, 2012
- ECI to Initiate Clinical Research for Cancer Therapy ECI301
April 13, 2012
- AnGes MG to Codevelop High Blood Pressure Treatment Oral Vaccine with Korean Company
April 13, 2012
- US Subsidiary’s CEO Resigns: DSP
April 13, 2012
- AnGes MG Obtains Pharmaceutical Use Patent in Japan for NF-κB Decoy Oligo
April 13, 2012
- Pfizer Focuses on Personalized Medicine for Oncology Area with Xalkori
April 12, 2012
- Teijin Pharma to Expand Overseas Marketing of Febuxostat in 117 Countries
April 12, 2012
- Taiho’s TS-1 Launched in UK, Approved in Hong Kong
April 12, 2012
- Toyota Tsusho Signs Agreement with Korean Venture to Become Sole Agent in Japan
April 12, 2012
- Sanofi Pasteur Targets Double Sales in Japan, Enters 4 Products Including IPV
April 11, 2012
- Takeda Pharmaceutical to Be Refunded 57.1 Bil. Yen for Transfer Pricing Taxation
April 11, 2012
- Sales Level Off for Year Ended Feb 2012 on Effects of Earthquake: Hisamitsu
April 11, 2012
- Sales of Ethical Drugs Up 8.7% in February: Crecon Report
April 10, 2012
- GSK Ties Up with Chiome for Antibody Generation Technology
April 10, 2012
- Fuso, Kaken to Jointly Market Topical Hemostatic Agent
April 10, 2012
- Ethical Drug Production in 2019 Predicted at 11 Trillion Yen: Yano Research Survey
April 10, 2012
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…